Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 7INDUSTRY 2OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 9Sarcoma 4Gastrointestinal 3Thoracic 2Genitourinary 1Dermatologic 1CNS 1Breast 1

Conditions

Breast Neoplasms 1

Interventions

Cyclophosphamide 423Trastuzumab 414Paclitaxel 375Docetaxel 314Capecitabine 266Letrozole 262Carboplatin 257Doxorubicin 213Tamoxifen 184Fulvestrant 176Epirubicin 176Radiotherapy 171Anastrozole 164pembrolizumab 152pertuzumab 147Surveys and Questionnaires 146Exercise 142exemestane 128Vinorelbine 127palbociclib 124Bevacizumab 123Magnetic Resonance Spectroscopy 120Blood Specimen Collection 120Drug Therapy 106Albumin-Bound Paclitaxel 105Gemcitabine 99130-nm albumin-bound paclitaxel 98pyrotinib 92eribulin 90Biopsy 88

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × cediranib × Breast × Clear all
NCT04090567 2026-03-05

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

M.D. Anderson Cancer Center

Phase 2 Recruiting
60 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡